LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
The launch of the fall television season is underway and with it, the influx of commercial interruptions. Lexus is offering an alternative to the traditional 30-minute sitcom with the debut of its fourth season of L Studio. The popular broadband channel, which has delivered such award-winning entertainment as “Web Therapy” and “Puppy Love,” is now partnering with Academy Award-winning screenwriter Diablo Cody (“Juno”) to debut her Web series “Red Band Trailer.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/52359-lexus-l-studio-diablo-cody-red-band-trailer-celebrity-interviews
Superstar model, producer, television host and designer, Heidi Klum is known for her cutting-edge style and trademark tresses. Now Unilever is tapping the sophisticated fashion icon to help launch new CLEAR SCALP & HAIR BEAUTY THERAPY™, a revolutionary line of nourishing shampoos and conditioners that turns the conventional hair care discussion on its head. This new approach “feeds scalp,” not just the ends, and gives women stronger, more beautiful hair in just seven days.
“When it comes to women’s hair care, the emphasis has traditionally been on the ends, yet 99 percent of hair’s natural strength and beauty comes from the scalp. Scalp is skin and it is important to care for and nourish it just as we care for our skin. NEW CLEAR SCALP & HAIR BEAUTY THERAPY™ feeds the scalp and creates the right foundation for stronger, more beautiful hair in just seven days,” says David Rubin, U.S. Haircare Marketing Director for Unilever.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55843-clear-scalp-and-hair-therapy
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Imagine your world in silence. Imagine the colour and vibrancy of your world sapped and living in silence. Imagine without communication how your world would be colourless, and you would feel boxed in, unable to communicate, share, grow. Your voice expresses who you are in the world, can you imagine losing your voice? Can you imagine your world in silence?
GivingvoiceUK and the giving voice campaign aim to secure access to speech and language therapy for all those who need it. Speech and language therapy means that people don't need to live in silence. No-one should have to live without speech; lend you support at http://www.givingvoiceuk.org/addyourvoice
